Apogee Therapeutics, Inc. (NASDAQ:APGE) CEO Sells $2,249,200.00 in Stock

Apogee Therapeutics, Inc. (NASDAQ:APGE) CEO Michael Thomas Henderson sold 40,000 shares of the company’s stock in a transaction dated Wednesday, October 2nd. The stock was sold at an average price of $56.23, for a total transaction of $2,249,200.00. Following the completion of the sale, the chief executive officer now owns 1,354,487 shares in the company, valued at $76,162,804.01. This represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Michael Thomas Henderson also recently made the following trade(s):

• On Wednesday, September 4th, Michael Thomas Henderson sold 40,000 shares of Apogee Therapeutics stock. The stock was sold at an average price of $47.62, for a total transaction of $1,904,800.00.
• On Wednesday, August 7th, Michael Thomas Henderson sold 40,000 shares of Apogee Therapeutics stock. The stock was sold at an average price of $40.62, for a total transaction of $1,624,800.00.

Apogee Therapeutics Stock Performance

Shares of APGE stock opened at $54.48 on Friday. Apogee Therapeutics, Inc. has a 52-week low of $14.19 and a 52-week high of $72.29. The company has a 50-day simple moving average of $49.67 and a two-hundred day simple moving average of $49.46. The company has a market capitalization of $3.18 billion, a price-to-earnings ratio of -10.38 and a beta of 2.75.

Apogee Therapeutics (NASDAQ:APGE) last issued its quarterly earnings data on Monday, August 12th. The company reported ($0.60) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.60). On average, sell-side analysts forecast that Apogee Therapeutics, Inc. will post -2.57 EPS for the current fiscal year.

Institutional Investors Weigh In On Apogee Therapeutics

Institutional investors have recently added to or reduced their stakes in the company. EntryPoint Capital LLC grew its position in Apogee Therapeutics by 44.7% in the 1st quarter. EntryPoint Capital LLC now owns 1,997 shares of the company’s stock worth $133,000 after purchasing an additional 617 shares in the last quarter. Kennedy Capital Management LLC bought a new position in shares of Apogee Therapeutics during the 1st quarter valued at approximately $212,000. Allspring Global Investments Holdings LLC bought a new position in shares of Apogee Therapeutics during the 2nd quarter valued at approximately $143,000. Ameritas Investment Partners Inc. grew its position in shares of Apogee Therapeutics by 111.2% during the 1st quarter. Ameritas Investment Partners Inc. now owns 4,126 shares of the company’s stock valued at $274,000 after acquiring an additional 2,172 shares during the period. Finally, Principal Financial Group Inc. bought a new position in shares of Apogee Therapeutics during the 1st quarter valued at approximately $339,000. 79.04% of the stock is owned by institutional investors.

About Apogee Therapeutics

Apogee Therapeutics, Inc, through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD.